ETR:MDG1 Medigene (MDG1) Stock Price, News & Analysis €1.76 -0.02 (-1.12%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range€1.62▼€1.8550-Day Range€1.02▼€2.0352-Week Range€1.60▼€5.51Volume5,390 shsAverage Volume306,207 shsMarket Capitalization$25.94 millionP/E RatioN/ADividend Yield1.31%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Medigene alerts: Email Address Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Medigene Stock (ETR:MDG1)Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.Read More MDG1 Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDG1 Stock News HeadlinesAugust 29, 2024 | nz.finance.yahoo.comMedigene AG (MDG1.SG)August 29, 2024 | nz.finance.yahoo.comMedigene AG (MDG1.MU)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 29, 2024 | uk.finance.yahoo.comMedigene AG (MDG1.VI)August 29, 2024 | nz.finance.yahoo.comMedigene AG (MDG1.HM)August 28, 2024 | markets.businessinsider.comMedigene to Present at Upcoming Investor ConferencesAugust 17, 2024 | finance.yahoo.comMedigene Second Quarter 2024 Earnings: Beats ExpectationsAugust 9, 2024 | uk.finance.yahoo.comMunich Re sees market volatility to continue for weeks or monthsSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 9, 2024 | finance.yahoo.comWuXi Biologics and Medigene link on T cell engagers for cancerJuly 30, 2024 | sg.finance.yahoo.comMedigene AG (MDG1.BE)July 23, 2024 | markets.businessinsider.comMedigene to Present at ESMO Congress 2024May 15, 2024 | finanznachrichten.deMedigene AG: Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRASMay 15, 2024 | finance.yahoo.comMedigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRASMay 14, 2024 | finance.yahoo.comMedigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital RaiseMay 2, 2024 | markets.businessinsider.comMedigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch ProteinApril 26, 2024 | finance.yahoo.comMedigene AG reports Financial Results and Business Update for Q1 2024April 25, 2024 | finance.yahoo.comMedigene presents streamlined 6-day, high stemness TCR-T therapy production processSee More Headlines Receive MDG1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:MDG1 CUSIPN/A CIKN/A Webwww.medigene.de Phone+49-89-2000330FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth7.12Net Income$-15,930,000.00 Net Margins-213.98% Pretax MarginN/A Return on Equity-63.93% Return on Assets-27.15% Debt Debt-to-Equity Ratio12.94 Current Ratio2.39 Quick Ratio5.85 Sales & Book Value Annual Sales$7.45 million Price / Sales3.48 Cash Flow€1.29 per share Price / Cash Flow1.37 Book Value€1.33 per share Price / Book1.32Miscellaneous Outstanding Shares14,740,000Free FloatN/AMarket Cap$25.94 million OptionableNot Optionable Beta0.84 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Selwyn Ho MB BS (Age 53)MBBS, CEO & Member of Executive Management Board Comp: $384.47kDr. Dolores J. SchendelChief Scientific Officer, Member of Executive Management Board and Head of Research & DevelopmentDr. Ernst-Ludwig Winnacker (Age 83)Co-Founder & Chairman Scientific Advisory Board Comp: $20kDr. Birger KohlertChief Financial OfficerPamela KeckVice President of Investor Relations & Corporate CommunicationsDr. Kirsty Crame M.D.VP and Head of Clinical Research & DevelopmentMore ExecutivesKey CompetitorsGenfitEPA:GNFTMorphoSysETR:MORBiotest AktiengesellschaftETR:BIOEssilor International Société AnonymeEPA:EIFielmann GroupFRA:FIEView All Competitors MDG1 Stock Analysis - Frequently Asked Questions How have MDG1 shares performed this year? Medigene's stock was trading at €1.53 at the start of the year. Since then, MDG1 stock has increased by 15.4% and is now trading at €1.76. View the best growth stocks for 2024 here. What other stocks do shareholders of Medigene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and This page (ETR:MDG1) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medigene AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Medigene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.